ReviewFrontiers in microbiology2024
Review in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Therapeutic efficacy and mechanisms of Xuebijing inFrontiers in pharmacology · 2025Pooled it
- Carbapenem-Resistant Acinetobacter baumannii: Resistance, Virulence, and Possible Dissemination Between Different Hospitals in Western Iran.Biochemical genetics · 2026Article
- Antibacterial efficacy of Nonea lutea-mediated silver and gold nanoparticles against multidrug-resistant clinical pathogens harboring virulence and resistance genes.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Comparative Population Genomics and Machine Learning Reveal a Distinct Regional Genomic Fingerprint of Middle EasternMicroorganisms · 2026Article
- Porphyrin and photodynamic therapy as tools against Acinetobacter baumannii.Antonie van Leeuwenhoek · 2026Review
- In Vitro Synergistic Effects of Selected Essential Oil Components Against ClinicalMolecules (Basel, Switzerland) · 2026Article
- Rapid delineation ofMicrobiology spectrum · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Repurposing Fingolimod as an Antibacterial and Antibiofilm Agent against Carbapenem-ResistantACS omega · 2026Article
- Article
- Redefining Antimicrobial Resistance inInternational journal of molecular sciences · 2026Review
- Changes in Susceptibility Profiles ofJournal of clinical medicine · 2026Article
- Extensively Drug-Resistant (XDR) and Pandrug-Resistant (PDR)Microorganisms · 2026Article
- Multiplex Lateral Flow Immunochromatographic Assay Is an Effective Method to Detect Carbapenemases in Non-SusceptibleJournal of clinical medicine · 2026Article
- Phenotype-Genotype Discordance in Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2026Review
- The Role of Combination Antibiotic Therapy in Combatting Drug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Imipenem-Induced Transcriptional Responses of Porin, Efflux Pumps, and Carbapenemase Genes in Clinical Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Plumbagin Disrupts Biofilm Integrity and Resistance Gene Expression in Carbapenem-ResistantJournal of microbiology and biotechnology · 2026Article
- Outer membrane vesicles of carbapenem-resistantMicrobiology spectrum · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.